A Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients With Advanced Biliary Tract Cancer

NCT07269158 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

160

Enrollment

OTHER

Sponsor class

Conditions

Biliary Tract Neoplasms
Advanced Cancer
Immunotherapy

Interventions

DRUG: Durvalumab or Pembrolizumab
DRUG: Durvalumab or Pembrolizumab + Levnatinib
DRUG: Durvalumab or Pembrolizumab + Venadaparib
DRUG: Durvalumab or Pembrolizumab + SCL-3010

Sponsor

Yonsei University